The aim of this report was to assess the added benefit of empagliflozin for the treatment of adults with type 2 diabetes mellitus in the following approved subindications:
http://ift.tt/2seQHjH
Πέμπτη 15 Ιουνίου 2017
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
-
http://ift.tt/2sxENoo
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου